Douglas G Mcneel

List of Publications by Citations

114 papers	3,398 citations	34 h-index	54 g-index
120 ext. papers	3,913 ext. citations	5.7 avg, IF	5.45 L-index

#	Paper	IF	Citations
114	Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. *Cancer Research*, **2009**, 69, 609-15	10.1	211
113	Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. *Journal of Clinical Oncology*, **2009**, 27, 4047-54	2.2	193
112	Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. *Clinical Cancer Research*, **2005**, 11, 7851-60	12.9	129
111	Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. *Breast Cancer Research and Treatment*, **2000**, 62, 245-52	4.4	127
110	Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. *Journal of Nuclear Medicine*, **2017**, 58, 162-168	8.9	110
109	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 1525-1535	12.9	95
108	DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. *Journal of Immunotherapy*, **2010**, 33, 639-47	5	94
107	Pilot trial of interleukin-2 and zoledronic acid to augment □T cells as treatment for patients with refractory renal cell carcinoma. *Cancer Immunology, Immunotherapy*, **2011**, 60, 1447-60	7.4	92
106	Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. *Journal of Immunology*, **2012**, 189, 5590-601	5.3	82
105	Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 110-120	8.8	73
104	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. *Cancer Immunology, Immunotherapy*, **2012**, 61, 1137-47	7.4	73
103	The SSX family of cancer-testis antigens as target proteins for tumor therapy. *Clinical and Developmental Immunology*, **2010**, 2010, 150591		71
102	Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. *Human Immunology*, **2010**, 71, 496-504	2.3	67
101	Molecular Imaging of Immunotherapy Targets in Cancer. *Journal of Nuclear Medicine*, **2016**, 57, 1487-1492	8.9	65
100	ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. *Molecular Pharmaceutics*, **2017**, 14, 1782-1789	5.6	62
99	ANTIBODY IMMUNITY TO PROSTATE CANCER ASSOCIATED ANTIGENS CAN BE DETECTED IN THE SERUM OF PATIENTS WITH PROSTATE CANCER. *Journal of Urology*, **2000**, 164, 1825-1829	2.5	61
98	PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. *Cancer Immunology Research*, **2015**, 3, 946-55	12.5	57

97	Endothelin receptor antagonists in cancer therapy. *Cancer Investigation*, **2007**, 25, 785-94	2.1	52
96	Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. *Prostate*, **2001**, 47, 222-9	4.2	50
95	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. *Oncotarget*, **2018**, 9, 25586-25596	3.3	48
94	Androgen deprivation and immunotherapy for the treatment of prostate cancer. *Endocrine-Related Cancer*, **2017**, 24, T297-T310	5.7	47
93	Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. *Cancer Research*, **2011**, 71, 6785-95	10.1	47
92	Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). *Vaccine*, **2006**, 24, 293-303	4.1	45
91	Identification of antigen-specific IgG in sera from patients with chronic prostatitis. *Journal of Clinical Immunology*, **2004**, 24, 492-502	5.7	44
90	Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. *Prostate*, **2007**, 67, 1781-90	4.2	42
89	Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. *Cancer Immunology, Immunotherapy*, **2007**, 56, 885-95	7.4	42
88	Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. *Journal of Clinical Immunology*, **2003**, 23, 62-72	5.7	42
87	GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. *Expert Opinion on Biological Therapy*, **2007**, 7, 1893-902	5.4	41
86	A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. *Cancer Immunology Research*, **2014**, 2, 988-99	12.5	40
85	HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. *Cancer Immunology, Immunotherapy*, **2010**, 59, 943-53	7.4	38
84	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. *OncoImmunology*, **2016**, 5, e1165377	7.2	38
83	Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 T Cells. *Cancer Immunology Research*, **2017**, 5, 630-641	12.5	35
82	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1999**, 93, 2653-2659	2.2	35
81	Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. *Clinical Cancer Research*, **2009**, 15, 3406-15	12.9	34
80	Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer. *Clinical Cancer Research*, **2014**, 20, 3692-704	12.9	33

79	An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. *Journal of Clinical Investigation*, **2009**, 119, 2031-41	15.9	33
78	Humoral immune responses to testis antigens in sera from patients with prostate cancer. *Cancer Immunity*, **2006**, 6, 1		32
77	Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study. *Investigational New Drugs*, **2007**, 25, 49-55	4.3	30
76	Preclinical and clinical development of DNA vaccines for prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 193-204	2.8	28
75	Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence. *Expert Review of Vaccines*, **2012**, 11, 1315-7	5.2	28
74	Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells. *Journal of Immunotherapy*, **2011**, 34, 569-80	5	27
73	DNA vaccines for prostate cancer. *Pharmacology & Therapeutics*, **2017**, 174, 27-42	13.9	25
72	DNA vaccines for the treatment of prostate cancer. *Expert Review of Vaccines*, **2010**, 9, 731-45	5.2	25
71	Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. *Prostate*, **2007**, 67, 1729-39	4.2	25
70	Newer therapies in advanced prostate cancer. *Clinical Prostate Cancer*, **2004**, 3, 150-6		25
69	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma **2016**, 4, 92		25
68	Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. *Immunobiology*, **2003**, 207, 179-86	3.4	24
67	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. *Journal of Clinical Oncology*, **2014**, 32, 5012-5012	2.2	24
66	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). *Human Vaccines and Immunotherapeutics*, **2015**, 11, 2469-74	4.4	22
65	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. *Journal of the National Cancer Institute*, **2020**, 112, 562-573	9.7	21
64	The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. *Cancer Immunology, Immunotherapy*, **2013**, 62, 585-96	7.4	21
63	Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. *International Journal of Urology*, **2006**, 13, 211-7	2.3	21
62	Immune-based therapies for prostate cancer. *Immunology Letters*, **2005**, 96, 3-9	4.1	21

61	Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with Zr-Df-Atezolizumab. *Bioconjugate Chemistry*, **2019**, 30, 1434-1441	6.3	20
60	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine **2018**, 6, 21		20
59	CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. *Cancer Immunology, Immunotherapy*, **2011**, 60, 781-92	7.4	20
58	Prostate cancer immunotherapy. *Current Opinion in Urology*, **2007**, 17, 175-81	2.8	20
57	Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. *Journal of Clinical Oncology*, **2019**, 37, 3507-3517	2.2	19
56	Immunotherapy for prostate cancer: False promises or true hope?. *Cancer*, **2016**, 122, 3598-3607	6.4	19
55	TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8 T Cells. *Cancer Immunology Research*, **2018**, 6, 1364-1374	12.5	19
54	T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. *Prostate*, **2012**, 72, 1239-47	4.2	16
53	Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand. *Journal of Immunotherapy*, **2005**, 28, 268-75	5	16
52	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab **2019**, 7, 23		15
51	DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. *Vaccine*, **2014**, 32, 1707-15	4.1	14
50	B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. *Oncotarget*, **2016**, 7, 67901-67918	5.5	14
49	Inducible expression of cancer-testis antigens in human prostate cancer. *Oncotarget*, **2016**, 7, 84359-84374	5.5	14
48	Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. *Prostate*, **2012**, 72, 487-98	4.2	13
47	Prioritization of cancer antigens: keeping the target in sight. *Expert Review of Vaccines*, **2009**, 8, 1657-61	5.2	13
46	Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. *Cancer Immunology Research*, **2017**, 5, 1074-1085	12.5	12
45	Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1661-1669	7.4	12
44	IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy. *Journal of Biomedicine and Biotechnology*, **2011**, 2011, 454861		12

43	MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis. *Journal of Immunotherapy*, **2007**, 30, 675-83	5	12
42	Therapeutic Cancer Vaccines: How Much Closer Are We?. *BioDrugs*, **2018**, 32, 1-7	7.9	11
41	A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. *Clinical Genitourinary Cancer*, **2013**, 11, 407-15	3.3	11
40	A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. *Clinical Genitourinary Cancer*, **2005**, 4, 215-8	3.3	11
39	Prostate cancer antigens and vaccines, preclinical developments. *Cancer Chemotherapy and Biological Response Modifiers*, **2005**, 22, 247-61		11
38	Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer. *Prostate*, **2011**, 71, 134-46	4.2	10
37	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. *Journal of Clinical Oncology*, **2015**, 33, 4500-4500	2.2	10
36	Mini-intronic plasmid vaccination elicits tolerant LAG3 CD8 T cells and inferior antitumor responses. *OncoImmunology*, **2016**, 5, e1223002	7.2	9
35	Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. *OncoImmunology*, **2012**, 1, 1546-1556	7.2	9
34	Cellular immunotherapies for prostate cancer. *Biomedicine and Pharmacotherapy*, **2007**, 61, 315-22	7.5	9
33	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 5162-5171	12.9	8
32	Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. *OncoImmunology*, **2018**, 7, e1456603	7.2	8
31	DNA Vaccines for Prostate Cancer. *Current Cancer Therapy Reviews*, **2012**, 8, 254-263	0.4	8
30	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination **2017**, 5, 56		7
29	His-tag ELISA for the detection of humoral tumor-specific immunity. *BMC Immunology*, **2008**, 9, 23	3.7	7
28	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. *Immunology Letters*, **2018**, 193, 1-10	4.1	7
27	Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes. *Prostate*, **2012**, 72, 730-40	4.2	6
26	Vaccination using peptides spanning the SYT-SSX tumor-specific translocation. *Expert Review of Vaccines*, **2012**, 11, 1401-4	5.2	6

25	DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2017**, 35, 168-168	2.2	6
24	SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. *Oncotarget*, **2016**, 7, 50997-51011	3.3	6
23	Immunotherapy for prostate cancer - recent progress in clinical trials. *Clinical Advances in Hematology and Oncology*, **2007**, 5, 465-74, 477-9	0.6	6
22	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. *OncoImmunology*, **2021**, 10, 1912892	7.2	5
21	Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). *Prostate*, **2017**, 77, 812-821	4.2	4
20	Sipuleucel-T: immunotherapy for advanced prostate cancer. *Open Access Journal of Urology*, **2011**, 3, 49-60		4
19	New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. *Update on Cancer Therapeutics*, **2006**, 1, 273-284		4
18	Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor. *Blood*, **1999**, 93, 2653-2659	2.2	4
17	Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles. *Frontiers in Immunology*, **2020**, 11, 1867	8.4	4
16	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**,	6.2	4
15	Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages **2020**, 8,		3
14	Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination **2013**, 1, 2		2
13	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors **2021**, 9,		2
12	Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease. *Journal of Clinical Oncology*, **2010**, 28, e680-3	2.2	1
11	Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer.. *Journal of Clinical Oncology*, **2013**, 31, 135-135	2.2	1
10	Prostate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. *Chinese Clinical Oncology*, **2013**, 2,	2.3	1
9	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). *Cancers*, **2020**, 12,	6.6	1
8	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon mediated suppression of immune checkpoint receptor expression.. *OncoImmunology*, **2022**, 11, 2054758	7.2	1

7	GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant.. *Cancer Immunology, Immunotherapy*, **2022**, 1	7.4	0
6	Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. *Journal of Immunology*, **2021**, 207, 720-734	5.3	0
5	DNA Vaccines **2017**, 183-198		
4	Androgen deprivation as a tumour-immunomodulating treatment. *Nature Reviews Urology*, **2020**, 17, 371-372	5.5	
3	DNA Vaccines **2014**, 1-16		
2	Reply to M.R. Smith et al. *Journal of Clinical Oncology*, **2010**, 28, e59-e59	2.2	
1	Engineering DNA Vaccines for Cancer Therapy **2014**, 449-471		